Q32Bio

Q32Bio

Q32Bio

Developing therapies targeting powerful regulators of innate and adaptive immunity to rebalance the immune system in severe autoimmune and inflammatory diseases
Type
B2c
Raised
$46M
Follow us
Alexa global traffic share
Latest funding
$46,000,000
Venture capital (Series A) - 2020
Atlas Venture Abingworth OrbiMed +3
Team Size
1–10
Employees
$46,000,000 Venture capital (Series A)
FinSMEs

Q32 Bio Raises $46M in Series A Funding